AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Emergent BioSolutions Inc. Director's Dealing 2019

Mar 21, 2019

32870_dirs_2019-03-21_e77b45f3-ba58-4aee-abae-f4d6e4eadc31.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2019-03-19

Reporting Person: Mulligan Seamus (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	48572	Direct
Common Stock	545590	Indirect

Footnotes

F1: Mr. Mulligan and his family, collectively hold an aggregate 100% equity interest in Nerano Pharma Ltd, which in turn is the direct owner of 545,590 shares of the Issuer's common stock.